1. Home
  2. BEAM vs UAA Comparison

BEAM vs UAA Comparison

Compare BEAM & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$28.62

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Under Armour Inc.

UAA

Under Armour Inc.

HOLD

Current Price

$5.14

Market Cap

2.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
UAA
Founded
2017
1996
Country
United States
United States
Employees
N/A
14400
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
UAA
Price
$28.62
$5.14
Analyst Decision
Buy
Hold
Analyst Count
12
16
Target Price
$50.75
$6.48
AVG Volume (30 Days)
1.9M
8.2M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$33.77
$1.57
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$4.13
52 Week High
$36.44
$8.15

Technical Indicators

Market Signals
Indicator
BEAM
UAA
Relative Strength Index (RSI) 45.77 32.23
Support Level $28.50 $4.76
Resistance Level $29.06 $6.71
Average True Range (ATR) 2.02 0.26
MACD -0.31 -0.15
Stochastic Oscillator 5.27 17.58

Price Performance

Historical Comparison
BEAM
UAA

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.

Share on Social Networks: